The purpose of the OX-NLA project is to develop a fast-acting nasal spray based on the antihistamine cetirizine for the treatment of allergic and non-allergic rhinitis (hay fever).
Orexo has developed a new formulation of cetirizine that can be administered directly in the nose by means of a spray. This was difficult in the past, since the substance itself causes irritation and stinging in the nasal mucous membrane. Administering the medication locally in the nose provides a faster effect on the allergic symptoms than if it is given orally as a tablet. The rapid effect also means that OX-NLA can be used safely and effectively for on-demand treatment.
| Name |
OX-NLA |
| Active substance |
Cetrizine |
| Phase |
Ready for phase III |
| Indication |
Rhinitis |
| Description |
Fast-acting nasal spray based on cetirizine |
| Partner |
Meda |
Market
Allergic rhinitis, or hay fever, causes swelling in the mucous membranes of the nose, which leads to nasal congestion, runny nose, itching and sneezing. The reaction can be triggered by e.g. contact with animals, dust or pollen.
Allergic rhinitis has become much more prevalent in the past 20 years and, today, about 25 percent of the population in the West suffers from allergic rhinitis. Rhinitis can also be non-allergic and triggered by odors, cold air and tobacco smoke.
In 2006, global sales of drugs for rhinitis amounted to approximately USD 10bn , where antihistamines in tablet form are most common, according to IMS.
Project status
Clinical Phase II studies of OX-NLA have shown good and fast-acting effects, which makes OX-NLA suitable for on-demand treatment. The nasal spray has favorable tolerance without causing local side effects in the form of stinging and pain.
The international specialty pharmaceutical company Meda has acquired the global rights to OX-NLA and combination products based on it. Meda is responsible for the product's further development.